Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review
The DOI matches its Crossref record.
Abstract
Article Abstract Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utilized with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs. J Clin Psychiatry 2014;75(4):e294-e307 © Copyright 2014 Physicians Postgraduate Press, Inc. Submitted: August 5, 2013; accepted January 16, 2014 (doi:10.4088/JCP.13r08714). Corresponding author: Baltazar Gomez-Mancilla, MD, PhD, Department of Neuroscience, Translational Medicine, Novartis Institutes of Biomedical Research, WSJ.210.25.5, CH-4056 Basel, Switzerland (baltazar.gomezmancilla@novartis.com).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
FragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
Self-citationMetabotropic glutamate receptor 5 as drug target for Fragile X syndrome
Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.004 · Cited by 106
Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115588287 · Cited by 87
“Drug discovery approaches have been successful in the past rescuing neuronal phenotypes in the context of FXS— namely, the regulation of altered neurologic signaling pathways.(17) In addition, FXS neurons are characterized for having a reduced density of postsynaptic dendrites; therefore, a number of assays have been…”
BackgroundSelf-citationGenomic Disorders in Psychiatry-What Does the Clinician Need to Know?
Lowther, C., Costain, G., Baribeau, D. A., & Bassett, A. S. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0831-5 · Cited by 41
Metadata
- Authors
- Hagerman, R. J., Des-Portes, V., Gasparini, F., Jacquemont, S., & Gomez-Mancilla, B.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-04-15
- Volume
- 75
- Issue
- 04
- Pages
- e294-e307
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1995251705
- Cited by
- 52
- References
- 0
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review. https://app.cochat.ai/papers/10.4088/jcp.13r08714
- The paper
- Hagerman, R. J., Des-Portes, V., Gasparini, F., Jacquemont, S., & Gomez-Mancilla, B. (2014). Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13r08714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.